Primary Surgery or Interval Debulking for Advanced Epithelial Ovarian Cancer: Does It Matter?

被引:26
|
作者
Markauskas, Algirdas [1 ]
Mogensen, Ole [1 ]
Christensen, Rene dePont [2 ]
Jensen, Pernille Tine [1 ]
机构
[1] Odense Univ Hosp, Dept Obstet & Gynaecol, DK-5000 Odense C, Denmark
[2] Univ Southern Denmark, Res Unit Gen Practice, Odense, Denmark
关键词
Debulking surgery; Epithelial ovarian cancer; Surgical complexity; Postoperative morbidity; Survival; NEOADJUVANT CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; QUALITY; RISK;
D O I
10.1097/IGC.0000000000000241
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aim of the present study was to investigate the surgical complexity, the postoperative morbidity, and the survival of the women after primary debulking surgery (PDS) and neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) for advanced epithelial ovarian cancer. Materials and Methods: We consecutively included all patients who underwent debulking surgery at our institution between January 2007 and December 2012 for stages IIIc and IV of epithelial ovarian cancer. Results: Of the 332 patients included, 165 (49.7%) underwent PDS, and 167 (50.3%) had NACT-IDS. Complete intraperitoneal cytoreduction was achieved in 70.9% after PDS and in 59.9 % after NACT-IDS. Residual disease of greater than 1 cm was left in 18.5% and 27.5% after PDS and NACT-IDS, respectively. Compared with NACT-IDS, PDS was associated with higher surgical complexity (P < 0.001), longer operating time (P < 0.001), greater blood loss (P < 0.001), longer hospitalization (P = 0.001), and a higher rate of major postoperative complications (26.7% vs 16.8%). No statistical difference in the median overall survival (OS) was found between the patients having complete cytoreduction and residual disease of 1 cm or less after NACT-IDS. Furthermore, no statistical difference in the median OS was found between the patients with macroscopic residual disease (<= 1 vs >1 cm) after NACT-IDS. Patients with residual disease of greater than 1 cm after PDS had a median OS of 15 months. Conclusions: We suggest that NACT-IDS may be a better treatment alternative for the group of highly selected women not suitable for PDS, where expected suboptimal cytoreduction does not have any appreciable survival benefit and exposes them for unnecessary risks. A substantial number of women who receive either PDS or NACT-IDS have greater than 1 cm of tumor tissue left after the operation. These women probably have no survival benefit from the operation, and future studies should focus on how to select these women preoperatively.
引用
收藏
页码:1420 / 1428
页数:9
相关论文
共 50 条
  • [1] Interval debulking surgery for advanced epithelial ovarian cancer
    Tangjitgamol, Siriwan
    Manusirivithaya, Sumonmal
    Laopaiboon, Malinee
    Lumbiganon, Pisake
    Bryant, Andrew
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (01):
  • [2] Interval debulking surgery for advanced epithelial ovarian cancer
    Tangjitgamol, Siriwan
    Manusirivithaya, Sumonmal
    Laopaiboon, Malinee
    Lumbiganon, Pisake
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (04):
  • [3] Interval debulking surgery for advanced epithelial ovarian cancer
    Tangjitgamol, Siriwan
    Manusirivithaya, Sumonmal
    Laopaiboon, Malinee
    Lumbiganon, Pisake
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (01):
  • [4] Interval debulking surgery for advanced epithelial ovarian cancer
    Tangjitgamol, Siriwan
    Manusirivithaya, Sumonmal
    Laopaiboon, Malinee
    Lumbiganon, Pisake
    Bryant, Andrew
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (04):
  • [5] Interval debulking surgery in advanced epithelial ovarian cancer
    Pecorelli, S
    Odicino, F
    Favalli, G
    BEST PRACTICE & RESEARCH IN CLINICAL OBSTETRICS & GYNAECOLOGY, 2002, 16 (04): : 573 - 583
  • [6] PRIMARY DEBULKING SURGERY OR NEOADJUVANT CHEMOTHERAPY FOLLOWED BY INTERVAL DEBULKING SURGERY FOR PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER?
    Mansouri, H.
    Zemni, I.
    Ben Safta, I.
    Achouri, L.
    Ben Hassouna, J.
    Hechiche, M.
    Chargui, R.
    Rahal, K.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A120 - A120
  • [7] Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer
    Morice, P
    Dubernard, G
    Rey, A
    Atallah, D
    Pautier, P
    Pomel, C
    Lhommé, C
    Duvillard, P
    Castaigne, D
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2003, 197 (06) : 955 - 963
  • [8] Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer
    Makar, Amin P.
    Trope, Claes G.
    Tummers, Philippe
    Denys, Hannelore
    Vandecasteele, Katrien
    ONCOLOGIST, 2016, 21 (06): : 745 - 754
  • [9] Neoadjuvant chemotherapy followed by interval debulking surgery versus primary debulking surgery in the advanced epithelial ovarian cancer - a retrospective cohort study
    Maricic, Slobodan
    Mandic, Aljosa
    Dejanovic, Ninoslav
    Kladar, Nebojsa
    Popovic, Marina
    Ivkovic-Kapicl, Tatjana
    Gutic, Bojana
    Kokanov, Dunja
    VOJNOSANITETSKI PREGLED, 2021, 78 (11) : 1193 - 1199
  • [10] INTERVAL DEBULKING SURGERY FOR ADVANCED OVARIAN CANCER IN ELDERLY PATIENTS (≥70 Y): DOES THE AGE MATTER?
    Pinelli, C.
    Morotti, M.
    Casarin, J.
    Tozzi, R.
    Ghezzi, F.
    Alazzam, M.
    Majd, H. Soleymani
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A509 - A509